{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T22:43:56Z","timestamp":1792622636205,"version":"4.5.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T00:00:00Z","timestamp":1740096000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T00:00:00Z","timestamp":1740096000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pharmacol Toxicol"],"DOI":"10.1186\/s40360-025-00872-9","type":"journal-article","created":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T12:03:54Z","timestamp":1740139434000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Real-world safety analysis of deutetrabenazine post-marketing: a disproportionality study leveraging the FDA Adverse Event Reporting System (FAERS) database"],"prefix":"10.1186","volume":"26","author":[{"given":"Guangwei","family":"Qing","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiyi","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanjian","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,21]]},"reference":[{"issue":"8","key":"872_CR1","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.4088\/JCP.tv17016ah4c","volume":"78","author":"CU Correll","year":"2017","unstructured":"Correll CU, Kane JM, Citrome LL. Epidemiology, prevention, and assessment of tardive dyskinesia and advances in treatment. J Clin Psychiatry. 2017;78(8):1136\u201347.","journal-title":"J Clin Psychiatry"},{"issue":"3","key":"872_CR2","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1002\/wps.20579","volume":"17","author":"M Carbon","year":"2018","unstructured":"Carbon M, Kane JM, Leucht S, Correll CU. Tardive dyskinesia risk with first- and second-generation antipsychotics in comparative randomized controlled trials: a meta-analysis. World Psychiatry. 2018;17(3):330\u201340.","journal-title":"World Psychiatry"},{"issue":"5","key":"872_CR3","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1212\/WNL.0b013e31829d86b6","volume":"81","author":"R Bhidayasiri","year":"2013","unstructured":"Bhidayasiri R, Fahn S, Weiner WJ, Gronseth GS, Sullivan KL, Zesiewicz TA. Evidence-based guideline: treatment of tardive syndromes: report of the guideline development subcommittee of the American academy of neurology. Neurology. 2013;81(5):463\u20139.","journal-title":"Neurology"},{"issue":"11","key":"872_CR4","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1177\/070674370505001110","volume":"50","author":"HC Margolese","year":"2005","unstructured":"Margolese HC, Chouinard G, Kolivakis TT, Beauclair L, Miller R, Annable L. Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 2: incidence and management strategies in patients with schizophrenia. Can J Psychiatry. 2005;50(11):703\u201314.","journal-title":"Can J Psychiatry"},{"issue":"8","key":"872_CR5","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1176\/ajp.156.8.1279","volume":"156","author":"WG Ondo","year":"1999","unstructured":"Ondo WG, Hanna PA, Jankovic J. Tetrabenazine treatment for tardive dyskinesia: assessment by randomized videotape protocol. Am J Psychiatry. 1999;156(8):1279\u201381.","journal-title":"Am J Psychiatry"},{"issue":"8","key":"872_CR6","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1002\/mds.25500","volume":"28","author":"R Reilmann","year":"2013","unstructured":"Reilmann R. Pharmacological treatment of chorea in Huntington\u2019s disease-good clinical practice versus evidence-based guideline. Mov Disord. 2013;28(8):1030\u20133.","journal-title":"Mov Disord"},{"issue":"12","key":"872_CR7","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1001\/jamaneurol.2016.3916","volume":"73","author":"R Reilmann","year":"2016","unstructured":"Reilmann R. Deutetrabenazine-Not a revolution but welcome evolution for treating chorea in huntington disease. JAMA Neurol. 2016;73(12):1404\u20136.","journal-title":"JAMA Neurol"},{"issue":"8","key":"872_CR8","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1001\/jamaneurol.2017.1352","volume":"74","author":"S Frank","year":"2017","unstructured":"Frank S, Stamler D, Kayson E, Claassen DO, Colcher A, Davis C, Duker A, Eberly S, Elmer L, Furr-Stimming E, et al. Safety of converting from tetrabenazine to deutetrabenazine for the treatment of chorea. JAMA Neurol. 2017;74(8):977\u201382.","journal-title":"JAMA Neurol"},{"issue":"9","key":"872_CR9","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1080\/14737175.2024.2376107","volume":"24","author":"P Moondra","year":"2024","unstructured":"Moondra P, Jimenez-Shahed J. Profiling deutetrabenazine extended-release tablets for tardive dyskinesia and chorea associated with Huntington\u2019s disease. Expert Rev Neurother. 2024;24(9):849\u201363.","journal-title":"Expert Rev Neurother"},{"key":"872_CR10","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.2147\/DDDT.S133205","volume":"12","author":"M Solmi","year":"2018","unstructured":"Solmi M, Pigato G, Kane JM, Correll CU. Treatment of tardive dyskinesia with VMAT-2 inhibitors: a systematic review and meta-analysis of randomized controlled trials. Drug Des Devel Ther. 2018;12:1215\u201338.","journal-title":"Drug Des Devel Ther"},{"issue":"11","key":"872_CR11","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1007\/s40263-022-00956-8","volume":"36","author":"S Frank","year":"2022","unstructured":"Frank S, Testa C, Edmondson MC, Goldstein J, Kayson E, Leavitt BR, Oakes D, O\u2019Neill C, Vaughan C, Whaley J, et al. The safety of deutetrabenazine for chorea in huntington disease: an Open-Label extension study. CNS Drugs. 2022;36(11):1207\u201316.","journal-title":"CNS Drugs"},{"issue":"3","key":"872_CR12","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.jagp.2021.08.003","volume":"30","author":"M Sajatovic","year":"2022","unstructured":"Sajatovic M, Finkbeiner S, Wilhelm A, Barkay H, Chaijale N, Gross N, Gordon MF. Long-Term safety and efficacy of deutetrabenazine in younger and older patients with tardive dyskinesia. Am J Geriatr Psychiatry. 2022;30(3):360\u201371.","journal-title":"Am J Geriatr Psychiatry"},{"issue":"2","key":"872_CR13","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.jaccao.2019.10.006","volume":"1","author":"K Anand","year":"2019","unstructured":"Anand K, Ensor J, Trachtenberg B, Bernicker EH. Osimertinib-Induced cardiotoxicity: A retrospective review of the FDA adverse events reporting system (FAERS). JACC CardioOncol. 2019;1(2):172\u20138.","journal-title":"JACC CardioOncol"},{"key":"872_CR14","doi-asserted-by":"publisher","first-page":"e071752","DOI":"10.1136\/bmj-2022-071752","volume":"379","author":"MM Dhodapkar","year":"2022","unstructured":"Dhodapkar MM, Shi X, Ramachandran R, Chen EM, Wallach JD, Ross JS. Characterization and corroboration of safety signals identified from the US food and drug administration adverse event reporting system, 2008-19: cross sectional study. BMJ. 2022;379:e071752.","journal-title":"BMJ"},{"issue":"8","key":"872_CR15","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1007\/s40264-021-01082-y","volume":"44","author":"J Setyawan","year":"2021","unstructured":"Setyawan J, Azimi N, Strand V, Yarur A, Fridman M. Reporting of thromboembolic events with JAK inhibitors: analysis of the FAERS database 2010\u20132019. Drug Saf. 2021;44(8):889\u201397.","journal-title":"Drug Saf"},{"issue":"8","key":"872_CR16","doi-asserted-by":"publisher","first-page":"591","DOI":"10.2165\/00002018-200427080-00010","volume":"27","author":"EG Brown","year":"2004","unstructured":"Brown EG. Using MedDRA: implications for risk management. Drug Saf. 2004;27(8):591\u2013602.","journal-title":"Drug Saf"},{"issue":"2","key":"872_CR17","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/j.jaip.2020.09.021","volume":"9","author":"RJ Yu","year":"2021","unstructured":"Yu RJ, Krantz MS, Phillips EJ, Stone CA Jr. Emerging causes of Drug-Induced anaphylaxis: A review of Anaphylaxis-Associated reports in the FDA adverse event reporting system (FAERS). J Allergy Clin Immunol Pract. 2021;9(2):819\u2013e829812.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"872_CR18","doi-asserted-by":"publisher","first-page":"862508","DOI":"10.3389\/fphar.2022.862508","volume":"13","author":"Y Shu","year":"2022","unstructured":"Shu Y, Ding Y, Liu Y, Wu P, He X, Zhang Q. Post-Marketing safety concerns with Secukinumab: A disproportionality analysis of the FDA adverse event reporting system. Front Pharmacol. 2022;13:862508.","journal-title":"Front Pharmacol"},{"issue":"1","key":"872_CR19","doi-asserted-by":"publisher","first-page":"21386","DOI":"10.1038\/s41598-024-71977-0","volume":"14","author":"Y Chen","year":"2024","unstructured":"Chen Y, Ren X, Dai Y, Wang Y. Pharmacovigilance study of the association between peripheral neuropathy and antibody-drug conjugates using the FDA adverse event reporting system. Sci Rep. 2024;14(1):21386.","journal-title":"Sci Rep"},{"key":"872_CR20","doi-asserted-by":"publisher","first-page":"773999","DOI":"10.3389\/fneur.2022.773999","volume":"13","author":"RA Hauser","year":"2022","unstructured":"Hauser RA, Barkay H, Fernandez HH, Factor SA, Jimenez-Shahed J, Gross N, Marinelli L, Wilhelm A, Alexander J, Gordon MF, et al. Long-Term deutetrabenazine treatment for tardive dyskinesia is associated with sustained benefits and safety: A 3-Year, Open-Label extension study. Front Neurol. 2022;13:773999.","journal-title":"Front Neurol"},{"issue":"21","key":"872_CR21","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1212\/WNL.0000000000003960","volume":"88","author":"HH Fernandez","year":"2017","unstructured":"Fernandez HH, Factor SA, Hauser RA, Jimenez-Shahed J, Ondo WG, Jarskog LF, Meltzer HY, Woods SW, Bega D, LeDoux MS, et al. Randomized controlled trial of deutetrabenazine for tardive dyskinesia: the ARM-TD study. Neurology. 2017;88(21):2003\u201310.","journal-title":"Neurology"},{"key":"872_CR22","doi-asserted-by":"publisher","first-page":"107580","DOI":"10.1016\/j.pharmthera.2020.107580","volume":"212","author":"J Koch","year":"2020","unstructured":"Koch J, Shi WX, Dashtipour K. VMAT2 inhibitors for the treatment of hyperkinetic movement disorders. Pharmacol Ther. 2020;212:107580.","journal-title":"Pharmacol Ther"},{"key":"872_CR23","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.parkreldis.2018.12.003","volume":"59","author":"TA Mestre","year":"2019","unstructured":"Mestre TA. Recent advances in the therapeutic development for huntington disease. Parkinsonism Relat Disord. 2019;59:125\u201330.","journal-title":"Parkinsonism Relat Disord"},{"issue":"1","key":"872_CR24","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1001\/jama.2016.8655","volume":"316","author":"S Frank","year":"2016","unstructured":"Frank S, Testa CM, Stamler D, Kayson E, Davis C, Edmondson MC, Kinel S, Leavitt B, Oakes D, O\u2019Neill C, et al. Effect of deutetrabenazine on chorea among patients with huntington disease: A randomized clinical trial. JAMA. 2016;316(1):40\u201350.","journal-title":"JAMA"},{"issue":"8","key":"872_CR25","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/S2215-0366(17)30236-5","volume":"4","author":"KE Anderson","year":"2017","unstructured":"Anderson KE, Stamler D, Davis MD, Factor SA, Hauser RA, Isoj\u00e4rvi J, Jarskog LF, Jimenez-Shahed J, Kumar R, McEvoy JP, et al. Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Psychiatry. 2017;4(8):595\u2013604.","journal-title":"Lancet Psychiatry"},{"issue":"10","key":"872_CR26","doi-asserted-by":"publisher","first-page":"e2129397","DOI":"10.1001\/jamanetworkopen.2021.29397","volume":"4","author":"B Coffey","year":"2021","unstructured":"Coffey B, Jankovic J, Claassen DO, Jimenez-Shahed J, Gertz BJ, Garofalo EA, Stamler DA, Wieman M, Savola JM, Gordon MF, et al. Efficacy and safety of Fixed-Dose deutetrabenazine in children and adolescents for tics associated with tourette syndrome: A randomized clinical trial. JAMA Netw Open. 2021;4(10):e2129397.","journal-title":"JAMA Netw Open"},{"issue":"6","key":"872_CR27","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1111\/pcn.12270","volume":"69","author":"PP Lerner","year":"2015","unstructured":"Lerner PP, Miodownik C, Lerner V. Tardive dyskinesia (syndrome): current concept and modern approaches to its management. Psychiatry Clin Neurosci. 2015;69(6):321\u201334.","journal-title":"Psychiatry Clin Neurosci"},{"issue":"2","key":"872_CR28","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.ncl.2020.01.004","volume":"38","author":"HH Bashir","year":"2020","unstructured":"Bashir HH, Jankovic J. Treatment of tardive dyskinesia. Neurol Clin. 2020;38(2):379\u201396.","journal-title":"Neurol Clin"},{"issue":"7","key":"872_CR29","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1080\/00325481.2015.1074031","volume":"127","author":"HR Khouzam","year":"2015","unstructured":"Khouzam HR. Identification and management of tardive dyskinesia: A case series and literature review. Postgrad Med. 2015;127(7):726\u201337.","journal-title":"Postgrad Med"},{"key":"872_CR30","doi-asserted-by":"publisher","first-page":"266","DOI":"10.5334\/tohm.199","volume":"4","author":"D Zutshi","year":"2014","unstructured":"Zutshi D, Cloud LJ, Factor SA. Tardive syndromes are rarely reversible after discontinuing dopamine receptor blocking agents: experience from a University-based movement disorder clinic. Tremor Other Hyperkinet Mov (N Y). 2014;4:266.","journal-title":"Tremor Other Hyperkinet Mov (N Y)"},{"key":"872_CR31","doi-asserted-by":"crossref","unstructured":"Andrade C. Antipsychotic medication continuation vs taper and discontinuation in patients with schizophrenia and other nonaffective psychotic disorders. J Clin Psychiatry. 2024;85(2).","DOI":"10.4088\/JCP.24f15363"},{"issue":"3","key":"872_CR32","doi-asserted-by":"publisher","first-page":"295","DOI":"10.4088\/JCP.09m05793yel","volume":"72","author":"SN Caroff","year":"2011","unstructured":"Caroff SN, Davis VG, Miller DD, Davis SM, Rosenheck RA, McEvoy JP, Campbell EC, Saltz BL, Riggio S, Chakos MH, et al. Treatment outcomes of patients with tardive dyskinesia and chronic schizophrenia. J Clin Psychiatry. 2011;72(3):295\u2013303.","journal-title":"J Clin Psychiatry"},{"key":"872_CR33","doi-asserted-by":"publisher","first-page":"13","DOI":"10.5334\/tohm.842","volume":"14","author":"M Golsorkhi","year":"2024","unstructured":"Golsorkhi M, Koch J, Pedouim F, Frei K, Bondariyan N, Dashtipour K. Comparative analysis of deutetrabenazine and valbenazine as VMAT2 inhibitors for tardive dyskinesia: A systematic review. Tremor Other Hyperkinet Mov (N Y). 2024;14:13.","journal-title":"Tremor Other Hyperkinet Mov (N Y)"},{"issue":"9","key":"872_CR34","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1002\/mdc3.13849","volume":"10","author":"J Jankovic","year":"2023","unstructured":"Jankovic J, Coffey B, Claassen DO, Jimenez-Shahed J, Gertz BJ, Garofalo EA, Stamler DA, Wieman M, Savola JM, Harary E, et al. Safety and efficacy of Long-Term deutetrabenazine use in children and adolescents with tics associated with tourette syndrome: an Open-Label extension study. Mov Disord Clin Pract. 2023;10(9):1388\u201398.","journal-title":"Mov Disord Clin Pract"},{"key":"872_CR35","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.2147\/TCRM.S279332","volume":"19","author":"S Frank","year":"2023","unstructured":"Frank S, Alakkas A. Clinical utility of deutetrabenazine as a treatment option for chorea associated with Huntington\u2019s disease and tardive dyskinesia. Ther Clin Risk Manag. 2023;19:1019\u201324.","journal-title":"Ther Clin Risk Manag"},{"issue":"4","key":"872_CR36","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/med.20187","volume":"31","author":"K Wimalasena","year":"2011","unstructured":"Wimalasena K. Vesicular monoamine transporters: structure-function, pharmacology, and medicinal chemistry. Med Res Rev. 2011;31(4):483\u2013519.","journal-title":"Med Res Rev"},{"issue":"8","key":"872_CR37","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1212\/WNL.0b013e3182a1ab4a","volume":"81","author":"EE Benarroch","year":"2013","unstructured":"Benarroch EE. Monoamine transporters: structure, regulation, and clinical implications. Neurology. 2013;81(8):761\u20138.","journal-title":"Neurology"},{"issue":"18","key":"872_CR38","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1080\/14656566.2016.1258063","volume":"17","author":"J Jankovic","year":"2016","unstructured":"Jankovic J. Dopamine depleters in the treatment of hyperkinetic movement disorders. Expert Opin Pharmacother. 2016;17(18):2461\u201370.","journal-title":"Expert Opin Pharmacother"},{"issue":"12","key":"872_CR39","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1007\/s40263-018-0580-y","volume":"32","author":"A Tarakad","year":"2018","unstructured":"Tarakad A, Jimenez-Shahed J. VMAT2 inhibitors in neuropsychiatric disorders. CNS Drugs. 2018;32(12):1131\u201344.","journal-title":"CNS Drugs"},{"key":"872_CR40","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.jns.2018.02.006","volume":"389","author":"LM Scorr","year":"2018","unstructured":"Scorr LM, Factor SA. VMAT2 inhibitors for the treatment of tardive dyskinesia. J Neurol Sci. 2018;389:43\u20137.","journal-title":"J Neurol Sci"},{"issue":"1","key":"872_CR41","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/s41422-023-00906-z","volume":"34","author":"Y Wang","year":"2024","unstructured":"Wang Y, Zhang P, Chao Y, Zhu Z, Yang C, Zhou Z, Li Y, Long Y, Liu Y, Li D, et al. Transport and Inhibition mechanism for VMAT2-mediated synaptic vesicle loading of monoamines. Cell Res. 2024;34(1):47\u201357.","journal-title":"Cell Res"},{"key":"872_CR42","doi-asserted-by":"crossref","unstructured":"Dalton MP, Cheng MH, Bahar I, Coleman JA. Structural mechanisms for VMAT2 Inhibition by tetrabenazine. Elife 2024, 12.","DOI":"10.7554\/eLife.91973.4"},{"issue":"1","key":"872_CR43","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/s42003-024-06195-5","volume":"7","author":"P Santos","year":"2024","unstructured":"Santos P, Heimler B, Koren O, Flash T, Plotnik M. Dopamine improves defective cortical and muscular connectivity during bilateral control of gait in Parkinson\u2019s disease. Commun Biol. 2024;7(1):495.","journal-title":"Commun Biol"},{"key":"872_CR44","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.neuroimage.2017.02.073","volume":"152","author":"M Gilat","year":"2017","unstructured":"Gilat M, Bell PT, Ehgoetz Martens KA, Georgiades MJ, Hall JM, Walton CC, Lewis SJG, Shine JM. Dopamine depletion impairs gait automaticity by altering cortico-striatal and cerebellar processing in Parkinson\u2019s disease. NeuroImage. 2017;152:207\u201320.","journal-title":"NeuroImage"},{"issue":"1","key":"872_CR45","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1523\/JNEUROSCI.2244-05.2006","volume":"26","author":"J Lu","year":"2006","unstructured":"Lu J, Jhou TC, Saper CB. Identification of wake-active dopaminergic neurons in the ventral periaqueductal Gray matter. J Neurosci. 2006;26(1):193\u2013202.","journal-title":"J Neurosci"},{"issue":"6","key":"872_CR46","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1002\/phar.2404","volume":"40","author":"CL Chow","year":"2020","unstructured":"Chow CL, Kadouh NK, Bostwick JR, VandenBerg AM. Akathisia and newer Second-Generation antipsychotic drugs: A review of current evidence. Pharmacotherapy. 2020;40(6):565\u201374.","journal-title":"Pharmacotherapy"},{"issue":"3","key":"872_CR47","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1097\/YCO.0b013e32832a16da","volume":"22","author":"R Kumar","year":"2009","unstructured":"Kumar R, Sachdev PS. Akathisia and second-generation antipsychotic drugs. Curr Opin Psychiatry. 2009;22(3):293\u20139.","journal-title":"Curr Opin Psychiatry"},{"key":"872_CR48","doi-asserted-by":"crossref","unstructured":"Gonz\u00e1lez-Rodr\u00edguez A, Monreal JA, Natividad M, Seeman MV. Collaboration between psychiatrists and other allied medical specialists for the treatment of delusional disorders. Healthc (Basel). 2022;10(9).","DOI":"10.3390\/healthcare10091729"},{"issue":"6","key":"872_CR49","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1111\/inm.12645","volume":"28","author":"M Ghosh","year":"2019","unstructured":"Ghosh M, Twigg D, Kutzer Y, Towell-Barnard A, De Jong G, Dodds M. The validity and utility of violence risk assessment tools to predict patient violence in acute care settings: an integrative literature review. Int J Ment Health Nurs. 2019;28(6):1248\u201367.","journal-title":"Int J Ment Health Nurs"},{"issue":"7","key":"872_CR50","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1093\/heapol\/czab064","volume":"36","author":"G Shapira","year":"2021","unstructured":"Shapira G, Ahmed T, Drouard SHP, Amor Fernandez P, Kandpal E, Nzelu C, Wesseh CS, Mohamud NA, Smart F, Mwansambo C, et al. Disruptions in maternal and child health service utilization during COVID-19: analysis from eight sub-Saharan African countries. Health Policy Plan. 2021;36(7):1140\u201351.","journal-title":"Health Policy Plan"},{"key":"872_CR51","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.brainresbull.2021.08.012","volume":"176","author":"K Pandey","year":"2021","unstructured":"Pandey K, Thurman M, Johnson SD, Acharya A, Johnston M, Klug EA, Olwenyi OA, Rajaiah R, Byrareddy SN. Mental health issues during and after COVID-19 vaccine era. Brain Res Bull. 2021;176:161\u201373.","journal-title":"Brain Res Bull"},{"issue":"8","key":"872_CR52","first-page":"e16999","volume":"13","author":"C Laboe","year":"2021","unstructured":"Laboe C, Jain A, Cardiel Sam H. Masked tardive dyskinesia in the coronavirus disease 2019 era. Cureus. 2021;13(8):e16999.","journal-title":"Cureus"}],"container-title":["BMC Pharmacology and Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-025-00872-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40360-025-00872-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-025-00872-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T12:05:48Z","timestamp":1740139548000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpharmacoltoxicol.biomedcentral.com\/articles\/10.1186\/s40360-025-00872-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,21]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["872"],"URL":"https:\/\/doi.org\/10.1186\/s40360-025-00872-9","relation":{},"ISSN":["2050-6511"],"issn-type":[{"value":"2050-6511","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,21]]},"assertion":[{"value":"1 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This project was submitted for review through Advocate Health and was waived as this study was deemed non-human subject related research.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"41"}}